Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | VDR | P11473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18603239 | 0.86 | HTT (0.56) | CYP2D6HTTCYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL10210972 | 0.86 | HTT (0.56) | CYP2D6HTTCYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL15898087 | 0.85 | CYP2D6 (0.49) | CYP2D6HTTCYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL15506544 | 0.85 | CYP2D6 (0.49) | CYP2D6HTTCYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL12146500 | 0.80 | CYP2D6 (0.45) | CYP2D6HTTCYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL2787828 | 0.79 | CYP2D6 (0.49) | CYP2D6CYP1A2KMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL181141 | 0.78 | CYP2D6 (0.54) | CYP2D6CYP1A2KMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL16985354 | 0.78 | CYP2D6 (0.48) | CYP2D6HTTCYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL21761015 | 0.77 | CYP2D6 (0.54) | CYP2D6HTTCYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL28909487 | 0.77 | CYP2D6 (0.54) | CYP2D6HTTCYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390705-A | 5-Oxa-2-azaspiro [3.4] octane derivatives as M4 agonists | 诺华股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-114555606-B | 5-Oxa-2-azaspiro [3.4] octane derivatives as M4 agonists | 诺华股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2024-05-02 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11485742-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2022-11-01 | — | — | US | disclosed |
| EP-4041737-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555606-A | 5-oxa-2-azaspiro [3.4] octane derivatives as M4 agonists | 诺华股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021070091-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485742-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | CYP2D6 958/4885HTT 4488/4885CYP1A2 568/4885 |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CYP2D6 958/4885HTT 4488/4885CYP1A2 568/4885 |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CYP2D6 958/4885HTT 4488/4885CYP1A2 568/4885 |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CYP2D6 945/4885HTT 4490/4885CYP1A2 561/4885 |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | CYP2D6 958/4885HTT 4488/4885CYP1A2 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.